FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to the CD40 receptor agonist protein, and can be used in medicine.
EFFECT: resulting CD40 receptor agonist protein containing two single-stranded fused polypeptides containing three soluble CD40L domains fused to the Fc fragment of the antibody can be used for effective treatment or diagnosis of CD40L-associated diseases.
14 cl, 10 dwg, 12 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SINGLE-CHAIN TRAIL-RECEPTOR AGONIST PROTEINS | 2015 |
|
RU2699285C2 |
| TRAIL R2-SPECIFIC MULTIMERIC SCAFFOLDS | 2011 |
|
RU2628699C2 |
| BIOLOGICALLY ACTIVATED DRUGS BASED ON CYTOKINES AND METHODS OF USING THEM | 2019 |
|
RU2819307C2 |
| CD40L-SPECIFIC CARCASS STRUCTURES DERIVED FROM Tn3, AND METHODS FOR USE THEREOF | 2012 |
|
RU2704992C2 |
| COMBINATION THERAPY FOR TREATMENT OF INFECTION CAUSED BY HEPATITIS B VIRUS | 2019 |
|
RU2777056C2 |
| NEW BISPECIFIC ANTIGEN-BINDING MOLECULES WITH CAPABILITY OF SPECIFICALLY BINDING TO CD40 AND FAP | 2018 |
|
RU2766234C2 |
| CSF1R-BASED CHIMERIC PROTEINS | 2018 |
|
RU2792239C2 |
| ACTIVIN-ActRIIa-Fc ANTAGONISTS AND USE THEREOF FOR TREATING OR PREVENTING BREAST CANCER | 2008 |
|
RU2473362C2 |
| ANTI-CD40-ANTIBODIES AND METHODS OF APPLICATION | 2012 |
|
RU2609647C2 |
| MONOVALENT CARRIER MODULES ACROSS BLOOD-BRAIN BARRIER | 2014 |
|
RU2694659C2 |
